Jinqiang Zhang, Chang Han, Nathan Ungerleider, Weina Chen, Kyoungsub Song, Ying Wang, Hyunjoo Kwon, Wenbo Ma, Tong Wu – 16 July 2018 – Functions of transforming growth factor‐β (TGF‐β) in the liver vary depending on specific cell types and their temporal response to TGF‐β during different stages of hepatocarcinogenesis (HCG). Through analysis of tumor tissues from hepatocellular carcinoma (HCC) patients, we were able to cluster hepatic epithelial cell‐derived TGF‐β gene signatures in association with distinct clinical prognoses.

Virginia Hernández‐Gea, Bogdan Procopet, Álvaro Giráldez, Lucio Amitrano, Candid Villanueva, Dominique Thabut, Luis Ibañez‐Samaniego, Gilberto Silva‐Junior, Javier Martinez, Joan Genescà, Christophe Bureau, Jonel Trebicka, Elba Llop, Wim Laleman, Jose Maria Palazon, Jose Castellote, Susana Rodrigues, Lise L. Gluud, Carlos Noronha Ferreira, Rafael Barcelo, Nuria Cañete, Manuel Rodríguez, Arnulf Ferlitsch, Jose Luis Mundi, Henning Gronbaek, Manuel Hernández‐Guerra, Romano Sassatelli, Alessandra Dell’Era, Marco Senzolo, Juan G.

Jaclyn LoPiccolo, Michael I. Brener, Kiyoko Oshima, Evan J. Lipson, James P. Hamilton – 16 July 2018

Donghee Kim, Andrew A. Li, Brandon J. Perumpail, Chiranjeevi Gadiparthi, Won Kim, George Cholankeril, Jeffrey S. Glenn, Stephen A. Harrison, Zobair M. Younossi, Aijaz Ahmed – 16 July 2018 – With recent improvements in the treatment of end‐stage liver disease (ESLD), a better understanding of the burden of cirrhosis and hepatocellular carcinoma (HCC) is needed in the United States. A population‐based study using the US Census and national mortality database was performed.

Diego A. Calvopina, Mark D. Chatfield, Anna Weis, Miranda A. Coleman, Manuel A. Fernandez‐Rojo, Charlton Noble, Louise E. Ramm, Daniel H. Leung, Peter J. Lewindon, Grant A. Ramm – 16 July 2018 – Cystic fibrosis (CF)‐associated liver disease (CFLD) is a hepatobiliary complication of CF. Current diagnostic modalities rely on nonspecific assessments, whereas liver biopsy is the gold standard to assess severity of fibrosis. MicroRNAs (miRNAs) regulate liver disease pathogenesis and are proposed as diagnostic biomarkers.

Jaclyn LoPiccolo, Michael I. Brener, Kiyoko Oshima, Evan J. Lipson, James P. Hamilton – 16 July 2018

Francesca Tucci, Valeria Calbi, Federica Barzaghi, Maddalena Migliavacca, Francesca Ferrua, Maria Ester Bernardo, Daniele Canarutto, Giulia Consiglieri, Salvatore Recupero, Francesco Calzatini, Michela Gabaldo, Caterina Lucano, Miriam Casiraghi, Silvia Darin, Francesca Dionisio, Sarah Marktel, Enza Cestone, Renato Finazzi, Giorgina Mieli‐Vergani, Enzo Boeri, Jonathan Appleby, Dalia Abd Elaziz, Fabio Ciceri, Alessandro Aiuti, Maria Pia Cicalese – 16 July 2018

Shengli Li, Zhixiang Hu, Yingjun Zhao, Shenglin Huang, Xianghuo He – 16 July 2018 – Alternative splicing (AS) is assumed to be a pivotal determinant for the generation of diverse transcriptional variants in cancer. However, the comprehensive dysregulation of AS and the prospective biological and clinical relevance in hepatocellular carcinoma (HCC) remain obscure. Here, we identified and depicted the AS landscape in HCC by performing reference‐based assembly of sequencing reads from over 600 RNA sequencing (RNA‐seq) libraries.

Jay Luther, Manish K. Gala, Nynke Borren, Ricard Masia, Russell P. Goodman, Ida Hatoum Moeller, Erik DiGiacomo, Alyssa Ehrlich, Andrew Warren, Martin L. Yarmush, Ashwin Ananthakrishnan, Kathleen Corey, Lee M. Kaplan, Sangeeta Bhatia, Raymond T. Chung, Suraj J. Patel – 16 July 2018 – Emerging data highlight the critical role for the innate immune system in the progression of nonalcoholic fatty liver disease (NAFLD).

Samuel J. Daniels, Diana J. Leeming, Mohammed Eslam, Ahmed M. Hashem, Mette J. Nielsen, Aleksander Krag, Morten A. Karsdal, Jane I. Grove, Indra Neil Guha, Takumi Kawaguchi, Takuji Torimura, Duncan McLeod, Jun Akiba, Philip Kaye, Bastiaan de Boer, Guruprasad P. Aithal, Leon A. Adams, Jacob George – 16 July 2018 – Given the high global prevalence of nonalcoholic fatty liver disease (NAFLD), the need for relevant noninvasive biomarkers and algorithms to accurately stage disease severity is a critical unmet medical need.